|Videos|May 10, 2019
Huma Sheikh, MD: Complementary Approaches for Multimodal Migraine Treatment
Author(s)Huma Sheikh, MD
The assistant professor of neurology at Mount Sinai Health System spoke about the recent trend toward approaching migraine in a more holistic fashion, and the incorporation of nonpharmacologic options for patients with the chronic headache condition.
Advertisement
“With something like migraine, where there is a genetic component but there is also a huge environmental component, patients are looking for ways that are more natural and try to get at the main underlying issue with their migraines—their triggers.”
A number of sessions and presentations at the 2019 American Academy of Neurology’s (AAN) Annual Meeting in Philadelphia, Pennsylvania, focused on migraine. More specifically, several were centered on the complementary and alternative approaches to treating migraine, such as neuromodulation devices.
Huma Sheikh, MD, assistant professor, Neurology, Mount Sinai Health System, recently opened a private practice, New York Headache and Neurology Medicine, to focus on these approaches for her patients. Despite the recent—and welcomed—approval of a number of preventive medications targeting calcitonin gene-related peptide (CGRP), and a few other oral abortive agents working their way toward a regulatory go-ahead, many patients have been refractory to oral treatments or simply don’t wish to undertake monthly or quarterly infusions. As such, the popularity of stimulation devices, acupuncture, and a number of other non-pharmacologic approaches to help combat chronic migraine and headaches has risen.
However, Sheikh noted that it’s important for physicians to utilize this more holistic approach to treating migraine in combination with the newly available agents. Ensuring that patients are being treated for this chronic condition with a multimodal methodology, she said, ensures not just that their experience with migraine will improve, but their overall health will improve.
To find out more about this shift in focus from organizations like AAN and the trend in medicine to approach patient care in a less segmented fashion, NeurologyLive spoke with Sheikh on the floor of the AAN annual meeting.
For more coverage of AAN 2019, click here .
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
- NeurologyLive® Friday 5 — September 12, 2025
September 12th 2025
- Expanding the Alzheimer Drug Development Pipeline
September 12th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive
1
MDA and PPMD Release Consensus Guidelines for Safe and Equitable Use of Gene Therapy in Duchenne
2
Expanding the Alzheimer Drug Development Pipeline
3
DORAs Carry Lower Real-World Abuse, New Phase 3 Argus Data, RAP-219 Meets Primary End Point
4
NeurologyLive® Friday 5 — September 12, 2025
5